Standardised ido-BR1 Cucumber Extract Improved Parameters Linked to Moderate Osteoarthritis in a Placebo-controlled Study

Curr Rheumatol Rev. 2023 Jun 5;19(3):345-351. doi: 10.2174/1573397119666230206105703.


Background: According to the World Health Organization, osteoarthritis (OA) is one of the 10 most disabling diseases in developed countries, with worldwide estimates of 9.6% prevalence in men and 18.0% in women over 60 years old. Its management is not well established and involves the use of high doses of painkillers coupled with anti-inflammatory agents.

Objective: In the search for alternatives to manage the disease, previous studies have shown superior properties of Q-ActinTM in managing OA-related pain compared with standard treatments. Qactin is a cucumber extract with the anti-inflammatory iminosugar idoBR1 standardised to over 1%. This study investigated the effects of different doses (20 mg, 100 mg) of Q-Actin in a longitudinal placebo-controlled experiment.

Methods: There were 101 patients with knee OA enrolled for the 180-day study, with 91 patients completing it. Patients were grouped into a placebo group (PLBO), as well as a 20mg dose (Q-Actin 1) and 100 mg dose (Q-Actin 2) groups. The PLBO group received cellulose in capsules identical to the Q-Actin capsules.

Results: There was a significant improvement in the pain-related parameters over time that was dose-dependent.

Conclusion: This study clearly demonstrated the effectiveness of Q-Actin compared to placebo in the management of pain related to moderate osteoarthritis.

Keywords: Cucumis sativus; Q-ActinTM; cucumber; idoBR1.; iminosugar; osteoarthritis.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Actins
  • Capsules / therapeutic use
  • Cucumis sativus*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Osteoarthritis, Knee* / drug therapy
  • Pain
  • Plant Extracts / therapeutic use
  • Treatment Outcome


  • Actins
  • Capsules
  • Plant Extracts